A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Novartis Investigative Site, Brussels

Novartis Investigative Site, Charleroi

Novartis Investigative Site, Berlin

Novartis Investigative Site, Marseille

Novartis Investigative Site, Caen

Novartis Investigative Site, Rozzano

Novartis Investigative Site, Bergamo

Novartis Investigative Site, Brescia

Novartis Investigative Site, Madrid

Novartis Investigative Site, Bordeaux

Novartis Investigative Site, Verona

Novartis Investigative Site, Seville

Novartis Investigative Site, Parma

Novartis Investigative Site, Meldola

Novartis Investigative Site, Strasbourg

Novartis Investigative Site, Tübingen

Los Angeles Hematology/Oncology Medical Group, Los Angeles

University of California Irvine Medical Center Chao Family SC, Orange

Novartis Investigative Site, Regensburg

Seattle Cancer Care Alliance, Seattle

Novartis Investigative Site, Singapore

Henry Ford Hospital SC, Detroit

Dartmouth Hitchcock Medical Center SC, Lebanon

Novartis Investigative Site, Nice

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Akashi

Novartis Investigative Site, Sendai

Novartis Investigative Site, Okayama

NKI-AVL, Department of Thoracic-Oncology, Amsterdam

Novartis Investigative Site, Seoul

Novartis Investigative Site, Seoul

Novartis Investigative Site, Barcelona